Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

NCT02629172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3043

Last updated 2020-02-24

No results posted yet for this study

Summary

The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.

Conditions

  • Chronic Hepatitis C Virus

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-05
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02629172 on ClinicalTrials.gov